Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
huwentoxin-IV
- Development stage
- Unknown
- Lead developer
- Sinobioway Biomedicine
- Modality
- Peptides
- Administration
- Intravenous, Subcutaneous
01
Overview
Huwentoxin-IV (HWTX-IV) is a 35-amino acid peptide toxin originally isolated from the venom of the Chinese bird spider (*Cyriopagopus schmidti*, formerly *Haplopelma huwenum*). Developed by Shandong Sinobioway Biomedicine (a subsidiary of Beijing Sinobioway Group), the peptide is a potent and selective antagonist of the voltage-gated sodium channel Nav1.7 (SCN9A). Nav1.7 is a critical mediator of pain signaling in the peripheral nervous system, and its inhibition is a validated strategy for treating various pain conditions without the addictive potential of opioids. HWTX-IV acts by binding to the voltage-sensing domain II of the channel, preventing its activation. The drug has been advanced into clinical development in China for the treatment of moderate-to-severe pain.
- Other names
- Huwena analgesic peptideHaplopelma huwenum toxin IV虎纹镇痛肽
02
Targets
AE1 (Anion exchange protein 1)SCN8A (NaV1.6)ATP2A1 (SERCA1)SCN9A (Sodium channel protein type 9 subunit alpha)
Beyond the preview
Go deeper on huwentoxin-IV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on huwentoxin-IV.